TS
ALNY icon

Thomas Steyer’s Alnylam Pharmaceuticals ALNY Stock Holding History

Thomas Steyer’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100,000
Closed -$39.8M – 175
2025
Q4 		$39.8M Hold
100,000
– – 0.17% 60
2025
Q3 		$45.6M Buy
+100,000
New +$40.7M 0.19% 59

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Thomas Steyer's ALNY Position: Q2 2024 in Review

Thomas Steyer sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2024, closing a stake of 2,000 shares — an estimated $299K sold.

Thomas Steyer first reported a position in ALNY in Q2 2017 and held it in 26 quarters. The position peaked at $202M in Q4 2021. 523 funds tracked by Wall St. Rank hold ALNY as of Q2 2024.

  • Thomas Steyer reported no remaining Alnylam Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Thomas Steyer sold 2,000 Alnylam Pharmaceuticals shares in Q2 2024, an estimated $299K.
  • Thomas Steyer first reported a position in Alnylam Pharmaceuticals in Q2 2017 and held it in 26 quarters.
  • Thomas Steyer's Alnylam Pharmaceuticals position peaked at $202M in Q4 2021.
  • 523 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2024.

Based on Farallon Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.